- Home
- CTNM vs CYBN Comparison
CTNM vs CYBN Comparison
Compare CTNM & CYBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTNM
- CYBN
- Stock Information
- Founded
- CTNM 2009
- CYBN 2019
- Country
- CTNM United States
- CYBN Canada
- Employees
- CTNM N/A
- CYBN N/A
- Industry
- CTNM
- CYBN Pharmaceuticals and Biotechnology
- Sector
- CTNM
- CYBN Health Care
- Exchange
- CTNM Nasdaq
- CYBN Nasdaq
- Market Cap
- CTNM 174.6M
- CYBN 176.0M
- IPO Year
- CTNM 2024
- CYBN N/A
- Fundamental
- Price
- CTNM $7.38
- CYBN $7.04
- Analyst Decision
- CTNM Strong Buy
- CYBN Strong Buy
- Analyst Count
- CTNM 4
- CYBN 3
- Target Price
- CTNM $22.50
- CYBN $85.00
- AVG Volume (30 Days)
- CTNM 196.1K
- CYBN 370.5K
- Earning Date
- CTNM 08-05-2025
- CYBN 08-13-2025
- Dividend Yield
- CTNM N/A
- CYBN N/A
- EPS Growth
- CTNM N/A
- CYBN N/A
- EPS
- CTNM N/A
- CYBN N/A
- Revenue
- CTNM N/A
- CYBN N/A
- Revenue This Year
- CTNM N/A
- CYBN N/A
- Revenue Next Year
- CTNM N/A
- CYBN N/A
- P/E Ratio
- CTNM N/A
- CYBN N/A
- Revenue Growth
- CTNM N/A
- CYBN N/A
- 52 Week Low
- CTNM $3.35
- CYBN $4.81
- 52 Week High
- CTNM $20.55
- CYBN $13.88
- Technical
- Relative Strength Index (RSI)
- CTNM N/A
- CYBN 40.31
- Support Level
- CTNM N/A
- CYBN $7.22
- Resistance Level
- CTNM N/A
- CYBN $7.75
- Average True Range (ATR)
- CTNM 0.00
- CYBN 0.35
- MACD
- CTNM 0.00
- CYBN -0.04
- Stochastic Oscillator
- CTNM 0.00
- CYBN 5.44
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.
About CYBN Cybin Inc.
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The Company is a clinical-stage neuropsychiatric company focused on advancing therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions. The Company is developing technologies and delivery systems aimed at improving the pharmacokinetics of its proprietary molecules while retaining the therapeutic benefit. These new molecules and delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.